Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

ClinicalTrials.gov ID: NCT00508365

Public ClinicalTrials.gov record NCT00508365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril

Study identification

NCT ID
NCT00508365
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
62 participants

Conditions and interventions

Conditions

Interventions

  • Carvedilol CR capsules Drug
  • Placebo Drug
  • Lisinopril Drug

Drug

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 24, 2007
Primary completion
Jun 2, 2008
Completion
Jun 2, 2008
Last update posted
Aug 8, 2017

2007 – 2008

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
GSK Investigational Site Anniston Alabama 36207
GSK Investigational Site Glendale Arizona 85308
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Beverly Hills California 90211
GSK Investigational Site Long Beach California 90806
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Miami Florida 33169
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Boise Idaho 83704
GSK Investigational Site Indianapolis Indiana 46260
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Hackensack New Jersey 07601
GSK Investigational Site Fargo North Dakota 58103
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site Oklahoma City Oklahoma 73132
GSK Investigational Site Portland Oregon 97239
GSK Investigational Site Austin Texas 78704
GSK Investigational Site Houston Texas 77081
GSK Investigational Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00508365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00508365 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →